IMNP : Summary for Immune Pharmaceuticals Inc. - Yahoo Finance

Immune Pharmaceuticals, Inc. (IMNP)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.21+0.02 (+10.17%)
At close: 4:00 PM EST
People also watch:
NVCNHTBXPTXSKLNMSTX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.19
Open0.19
Bid0.21 x 9900
Ask0.23 x 15000
Day's Range0.19 - 0.23
52 Week Range0.16 - 0.87
Volume14,930,307
Avg. Volume5,235,198
Market Cap29.55M
Beta2.42
PE Ratio (TTM)-0.31
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Two Nano-Cap Pharma Stocks To Watch Right Now
    Insider Monkey8 days ago

    Two Nano-Cap Pharma Stocks To Watch Right Now

    Pharmaceutical stocks have had a tough year, with landmark ETFs like the PowerShares Dynamic Pharmaceuticals(ETF) (NYSEARCA:PJP) down about 18.7% since January, the iShares Dow Jones US Pharm Indx (ETF) (NYSEARCA:IHE) having lost 12.7%, and the SPDR S&P Pharmaceuticals (ETF) (NYSEARCA:XPH) having plummeted 22.3%. In this context of depressed valuations, some stocks might offer very attractive […]

  • PR Newswire18 days ago

    Immune Pharmaceuticals Announces Immuno-Oncology R&D Update on December 8, 2016

    NEW YORK, Nov. 22, 2016 /PRNewswire/ -- Immune Pharmaceuticals (IMNP) (Immune) announced today that it will hold an Immuno-Oncology R&D Update for investors on December 8, 2016 in New York City. Immune management and several Oncology Key Opinion leaders will review development plans and milestones for Ceplene® and other pipeline assets to be funded separately in the recently announced Immune subsidiary, Cytovia Oncology. Prior to the Immuno-Oncology R&D Update, the Ceplene Scientific Advisory Board (SAB) will meet on December 4, 2016 in San Diego where the American Society of Hematology is holding its annual meeting.

  • PR Newswire23 days ago

    Immune Pharmaceuticals Secures Up to $11 Million in New Financing to be Deployed With a Focus on Bertilimumab Clinical Development

    NEW YORK, Nov. 17, 2016 /PRNewswire/ -- Immune Pharmaceuticals (IMNP) (Immune) announced today that it has secured up to $11 million in new financing from a single family office that is an existing investor. Dr. Daniel Teper, Immune's CEO commented: "We appreciate the continuous commitment of our investors to support this financing of Immune, which will be dedicated to the advancement of bertilimumab clinical development. Immune continues to accrue patients in two phase 2 clinical trials for bertilimumab, a first-in-class monoclonal antibody targeting eotaxin-1: an open label 10 patient trial in the treatment of bullous pemphigoid, an orphan auto-immune dermatological condition, and a double-blind, placebo-controlled, 42 patient trial in moderate-to-severe ulcerative colitis, a gastrointestinal inflammatory condition.